Skip to main content
Clinical Trials/IRCT20240116060710N1
IRCT20240116060710N1
Recruiting
Phase 3

Evaluation the effect of Botulinum toxin type A Masport 500 injection on improving pain and quality of life in patients with diabetic neuropathy.

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Shahid Beheshti University of Medical Sciences
Enrollment
30
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Definite diabetic neuropathy in the plantar area of ??both feet confirmed by NCV.
  • diabetes at least for three years
  • Consistency of the patient's medication for diabetic neuropathy for at least one month before entering the study
  • Filling out a personal consent form to enter the study

Exclusion Criteria

  • Having an underlying disease involving the peripheral nerves that causes symptoms similar to diabetic neuropathy in the plantar area.
  • Change in the patient's medication for diabetic neuropathy during at least one month before entering the study
  • History of myasthenia gravis
  • Allergy to botulinum toxin
  • kidney dysfunction
  • Having a history of alcohol consumption
  • Opioid addiction
  • Presence of pain with a typical dermatomal pattern caused by radiculopathy
  • Lack of patient consent to participate in the study

Outcomes

Primary Outcomes

Not specified

Similar Trials